Russian Heart Failure Journal 2011year Prognostic role of changes in NT-proBNP level during combined therapy of patients with heart failure


To access this material please log in or register

Register Authorize
2011/

Prognostic role of changes in NT-proBNP level during combined therapy of patients with heart failure

Mezhonov E. M.

Keywords: N-terminal brain natriuretic propeptide (NT-proBNP), prognosis, heart failure

DOI: 10.18087/ rhfj.2011.2.1462

Background. It is not clear if the dynamic of NT-proBNP level during therapy can reflect the long-term prognosis. Objective. To study the prognostic significance of dynamic of NT-proBNP plasma level in patients with LVSD receiving standard therapy in one-year prospective study. Materials and methods. The study included 84 patients aged 23 to 70 years (mean age 54±8.1 years) with LVSD (LVEF <40 %). All patients underwent 6 min walk test, echocardiography, detection of NT-proBNP plasma level, assessment the cli­nical status with SHOKS. Median follow-up was 18 months. Results. Baseline NT-proBNP high level (3,000 pg / ml) and the absence of its decrease, as well as increase of its plasma level during treatment period was associated with a worse prognosis. The reduction of plasma level was associated with better prognosis. Thus, repeated definition of NT-proBNP plasma level can identify patients at increased risk for more intensive observation and aggressive pathogenic therapy.
  1. Бугримова М. А., Савина Н. М., Ваниева О. С. Мозговой натрийуретический пептид как маркер и фактор прогноза при хронической сердечной недостаточности. Кардиология. 2006;46 (1):51–64.
  2. Cleland JGF, Swedberg K, Follath F et al. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–463.
  3. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49 (16):1733–1739.
  4. Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic pepetide as a rapid point-of-care test for screening patients undergoing ecgocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141 (3):367–374.
  5. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355 (9210):1126–1130.
  6. Yoshimura M, Mizuno Y, Nakayama M et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med. 2002;112 (9):716–720.
  7. Maisel A, Mueller C, Adams K Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10 (9):824–839.
  8. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J. 2007;28 (2):177–182.
Mezhonov E. M. Prognostic role of changes in NT-proBNP level during combined therapy of patients with heart failure. Russian Heart Failure Journal. 2011;12(2):73-78.

To access this material please log in or register

Register Authorize
Ru En